Singh Udai P, Singh Narendra P, Singh Balwan, Mishra Manoj K, Nagarkatti Mitzi, Nagarkatti Prakash S, Singh Shree Ram
Pathology and Microbiology and Immunology, School of Medicine, University of South Carolina, Columbia, SC 29208, USA.
Front Biosci (Schol Ed). 2010 Jun 1;2(3):993-1008. doi: 10.2741/s115.
The incidence and prevalence of Crohn's disease and ulcerative colitis, the two major forms of inflammatory bowel disease (IBD), are rising. According to some estimates >1 million new cases of IBD arise in the United States annually. The conventional therapies available for IBD range from anti-inflammatory drugs to immunosuppressive agents, but these therapies generally fail to achieve satisfactory results due to their side effects. Interest in a new therapeutic option, that is, biological therapy, has gained much momentum recently due to its focus on different stages of the inflammatory process. Stem cell (SC) research has become a new direction for IBD therapy due to our recent understanding of cell populations involved in the pathogenic process. To this end, hematopoietic and mesenchymal stem cells are receiving more attention from IBD investigators. The intestinal environment, with its crypts and niches, supports incoming embryonic and hematopoietic stem cells and allows them to engraft and differentiate. The above findings suggest that, in the future, SC-based therapy will be a promising alternative to conventional therapy for IBD. In this review, we discuss SCs as potential therapeutic targets for future treatment of IBD.
克罗恩病和溃疡性结肠炎是炎症性肠病（IBD）的两种主要形式，它们的发病率和患病率正在上升。据一些估计，美国每年有超过100万例新发IBD病例。IBD的传统治疗方法从抗炎药到免疫抑制剂不等，但由于这些疗法的副作用，它们通常无法取得令人满意的效果。由于关注炎症过程的不同阶段，一种新的治疗选择，即生物疗法，最近获得了很大的发展势头。由于我们最近对参与致病过程的细胞群体的了解，干细胞（SC）研究已成为IBD治疗的一个新方向。为此，造血干细胞和间充质干细胞正受到IBD研究人员越来越多的关注。具有隐窝和龛的肠道环境支持进入的胚胎干细胞和造血干细胞，并使它们能够植入和分化。上述发现表明，未来基于干细胞的疗法将是IBD传统疗法的一种有前途的替代方法。在这篇综述中，我们讨论了干细胞作为未来IBD治疗潜在靶点的情况。
